Comments

You must log in or register to comment.

bitswede t1_jaeidt4 wrote

Sweden, and I believe most other European countries, have a ceiling for how much you have to pay per year for prescribed medicines. In Sweden the limit is around 575€ per year with a 50% rebate kicking in at 120€. This rebate gradually increases to 90% which it hits at 415€.

Edit: misread the infographic i used. Actual ceiling is 235€ out of pocket, after that your prescriptions are filled at no cost to you.

69

floralvas t1_jaeiryf wrote

And insulin is totally free of you have diabetes which is nice!

34

colouredinthelines t1_jaeihmc wrote

Certainly patents aren’t a factor since Banting and Best sold the patent for insulin to the university of Toronto for $1.

20

TrainDriverDave t1_jaekryi wrote

In the UK, prescriptions are free to diabetics, so I'm a bit surprised you have a non-zero unit cost. Is your graph the cost to patients, or to the health service?

10

11160704 t1_jaeqsfq wrote

It sounds like the market price in the given country.

9

goodluckonyourexams t1_jaejjpr wrote

"Adjusted net national income is GNI minus consumption of fixed capital and natural resources depletion."

why not use average income?

9

goodluckonyourexams t1_jaek1lc wrote

Average Income is also known as Per-capita income. It measures the average income earned per person in a given area in specified year. National Income is the sum total of all the goods and services produced in a country along with the income obtained from all foreign countries.

6

cleaning_my_room_ t1_jaetkqj wrote

Are these the same type of insulin? Somehow I expect the answer to be no.

I have heard doctors say that the type of insulin US health insurers cover is massively more expensive than other types that are available in generic form and that have statistically similar clinical outcomes for patients.

The expensive kind keeps blood glucose in a narrower range, which is how they convinced insurers to require it, but clinical studies have shown no improvement in patient outcomes over the cheaper insulin.

4